- Home
- SVII vs DBVT Comparison
SVII vs DBVT Comparison
Compare SVII & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- DBVT
- Stock Information
- Founded
- SVII 2021
- DBVT 2002
- Country
- SVII United States
- DBVT France
- Employees
- SVII N/A
- DBVT N/A
- Industry
- SVII Blank Checks
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVII Finance
- DBVT Health Care
- Exchange
- SVII Nasdaq
- DBVT Nasdaq
- Market Cap
- SVII 112.1M
- DBVT 102.0M
- IPO Year
- SVII 2022
- DBVT N/A
- Fundamental
- Price
- SVII $11.33
- DBVT $4.40
- Analyst Decision
- SVII
- DBVT Strong Buy
- Analyst Count
- SVII 0
- DBVT 2
- Target Price
- SVII N/A
- DBVT $22.50
- AVG Volume (30 Days)
- SVII 337.0
- DBVT 28.3K
- Earning Date
- SVII 01-01-0001
- DBVT 03-06-2025
- Dividend Yield
- SVII N/A
- DBVT N/A
- EPS Growth
- SVII 13.16
- DBVT N/A
- EPS
- SVII 0.36
- DBVT N/A
- Revenue
- SVII N/A
- DBVT $12,515,000.00
- Revenue This Year
- SVII N/A
- DBVT N/A
- Revenue Next Year
- SVII N/A
- DBVT $2,860.00
- P/E Ratio
- SVII $31.42
- DBVT N/A
- Revenue Growth
- SVII N/A
- DBVT 125.54
- 52 Week Low
- SVII $10.91
- DBVT $0.44
- 52 Week High
- SVII $11.70
- DBVT $5.42
- Technical
- Relative Strength Index (RSI)
- SVII 59.82
- DBVT 54.39
- Support Level
- SVII $11.20
- DBVT $4.18
- Resistance Level
- SVII $11.24
- DBVT $4.47
- Average True Range (ATR)
- SVII 0.00
- DBVT 0.28
- MACD
- SVII -0.00
- DBVT -0.04
- Stochastic Oscillator
- SVII 50.00
- DBVT 71.34
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.